Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies - Concepedia

Concepedia

Publication | Closed Access

Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

192

Citations

0

References

2011

Year

Conn Harrington, Sharon Sawchak, Carl Chiang, J. Davies, Carly Donovan, Ann M. Saunders, Michael C. Irizarry, Barbara Jeter, Marina Zvartau‐Hind, C H van Dyck,

Current Alzheimer Research

Abstract

No evidence of statistically or clinically significant efficacy in cognition or global function was detected for 2 mg or 8 mg RSG XR as adjunctive therapy to ongoing AChEIs. There was no evidence of an interaction between treatment and APOE status. Safety and tolerability of RSG XR was consistent with the known profile of rosiglitazone.